S3Ab, a novel antibody targeting B lymphocytes, is a potential therapeutic agent for B-lineage malignancies

References

• Brower V. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers. J Natl Cancer Inst. 2015;107:djv112-djv112.
   Google Scholar
• Brentjens RJ, Davila ML, Riviere I, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5:177ra38.
   PubMed Web of Science ®Google Scholar
• Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377:2531–2544.
   PubMed Web of Science ®Google Scholar
• Novartis Pharmaceuticals Corporation. Kymriah (tisagenlecleucel): Prescribing information. East Hanover, New Jersey, USA. 2018.
   Google Scholar
• Ruella M, Barrett DM, Kenderian SS, et al. Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies. J Clin Invest. 2016;126:3814–3826.
   PubMed Web of Science ®Google Scholar
• Xiao W, Salem D, McCoy CS, et al. Early recovery of circulating immature B cells in B-lymphoblastic leukemia patients after CD19 targeted CAR T cell therapy: a pitfall for minimal residual disease detection. Cytometry B Clin Cytom. 2018;94:434–443.
   PubMed Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24:20–28.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs. 2003;63:803–843.
   PubMed Web of Science ®Google Scholar
• Jones RB, Furuta S, Tervaert JW, et al. Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Dis. 2015;74:1178–1182.
   PubMed Web of Science ®Google Scholar
• Andrade-Ortega L, Irazoque-Palazuelos F, Lopez-Villanueva R, et al. Efficacy of rituximab versus cyclophosphamide in lupus patients with severe manifestations. A randomized and multicenter study. Reumatol Clin. 2010;6:250–255.
   PubMedGoogle Scholar
• Tribolet L, Cantacessi C, Pickering DA, et al. Probing of a human proteome microarray with a recombinant pathogen protein reveals a novel mechanism by which hookworms suppress B-cell receptor signaling. J Infect Dis. 2015;211:416–425.
   PubMed Web of Science ®Google Scholar
• Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94:193–205.
   PubMed Web of Science ®Google Scholar
• Adem J, Eray M, Eeva J, et al. Advantages of targeting B cell receptor complex to treat B-cell derived autoimmune diseases and lymphomas. Mol Immunol. 2017;88:135–137.
   PubMed Web of Science ®Google Scholar
• Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16:704–715.
   PubMed Web of Science ®Google Scholar
• Pfeifer M, Zheng B, Erdmann T, et al. Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes. Leukemia. 2015;29:1578–1586.
   PubMed Web of Science ®Google Scholar
• Young RM, Shaffer AR, Phelan JD, et al. B-cell receptor signaling in diffuse large B-cell lymphoma. Semin Hematol. 2015;52:77–85.
   PubMed Web of Science ®Google Scholar
• Jang C, Machtaler S, Matsuuchi L. The role of Ig-α/β in B cell antigen receptor internalization. Immunol Lett. 2010;134:75–82.
   PubMed Web of Science ®Google Scholar
• Mason DY, Cordell JL, Brown MH, et al. CD79α a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood. 1995;86:1453–1459.
   PubMed Web of Science ®Google Scholar
• Dworzak MN, Fritsch G, Froschl G, et al. Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79α expression precedes CD19 in early B-cell ontogeny. Blood. 1998;92:3203–3209.
   PubMed Web of Science ®Google Scholar
• Chu PG, Arber DA. CD79: a review. Appl Immunohistochem Mol Morphol. 2001;9:97–106.
   PubMedGoogle Scholar
• Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–497.
   PubMed Web of Science ®Google Scholar
• Li S, Tang Y. Accurate determination of internalization for target binding antibody using papain digestion and flow cytometry. Hybridoma. 2010;29:133–139.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Karpova MB, Schoumans J, Ernberg I, et al. Raji revisited: cytogenetics of the original Burkitt's lymphoma cell line. Leukemia. 2005;19:159–161.
   PubMed Web of Science ®Google Scholar
• Niemann CU, Wiestner A. B-cell receptor signaling as a driver of lymphoma development and evolution. Semin Cancer Biol. 2013;23:410–421.
   PubMed Web of Science ®Google Scholar
• Hardy IR, Anceriz N, Rousseau F, et al. Anti-CD79 antibody induces B cell anergy that protects against autoimmunity. J Immunol. 2014;192:1641–1650.
   PubMed Web of Science ®Google Scholar
• Dahal LN, Cragg MS. Rehabilitation or the death penalty: autoimmune B cells in the dock. Eur J Immunol. 2015;45:687–691.
   PubMed Web of Science ®Google Scholar
• Mason DY, van Noesel CJ, Cordell JL, et al. The B29 and mb-1 polypeptides are differentially expressed during human B cell differentiation. Eur J Immunol. 1992;22:2753–2756.
   PubMed Web of Science ®Google Scholar